アレルギー性喘息(Allergic Asthma):治療薬開発パイプライン動向(世界、2015年上半期版)

Global Markets Directが発行した調査報告書(GMDHC6145IDB)
◆英語タイトル:Allergic Asthma - Pipeline Review, H1 2015
◆商品コード:GMDHC6145IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:142
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界におけるアレルギー性喘息(Allergic Asthma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・アレルギー性喘息(Allergic Asthma)の概要
・アレルギー性喘息(Allergic Asthma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・アレルギー性喘息(Allergic Asthma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・アレルギー性喘息(Allergic Asthma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・アレルギー性喘息(Allergic Asthma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Allergic Asthma – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Allergic Asthma – Pipeline Review, H1 2015’, provides an overview of the Allergic Asthma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Allergic Asthma Overview 10
Therapeutics Development 11
Pipeline Products for Allergic Asthma – Overview 11
Pipeline Products for Allergic Asthma – Comparative Analysis 12
Allergic Asthma – Therapeutics under Development by Companies 13
Allergic Asthma – Therapeutics under Investigation by Universities/Institutes 16
Allergic Asthma – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Allergic Asthma – Products under Development by Companies 20
Allergic Asthma – Products under Investigation by Universities/Institutes 22
Allergic Asthma – Companies Involved in Therapeutics Development 23
ALK-Abello A/S 23
Allergopharma Joachim Ganzer KG 24
Array BioPharma Inc. 25
Aslan Pharmaceuticals Pte. Ltd. 26
Asmacure Ltee 27
BioTech Tools s.a. 28
Fountain Biopharma Inc. 29
Genentech, Inc. 30
Infinity Pharmaceuticals, Inc. 31
Kineta, Inc. 32
Marinomed Biotechnologie GmbH 33
NeoPharm Co., Ltd. 34
Novartis AG 35
Nuvo Research Inc. 36
Panacea Biotec Limited 37
Peptinnovate Limited 38
Pharmaxis Limited 39
Portola Pharmaceuticals, Inc. 40
Protectimmun GmbH 41
Pulmatrix, Inc. 42
Stallergenes S.A. 43
sterna biologicals Gmbh & Co KG 44
Verona Pharma Plc 45
Allergic Asthma – Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(fluticasone propionate + salmeterol xinafoate) – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Acaroid – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AcTMP-1 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
allergenic pollen extract of timothy – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Arabinogalactan – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ARRY-502 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ASLAN-004 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ASM-024 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ASM-8 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dalazatide – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Drug to Inhibit PI3 Kinase Delta for Asthma – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
duvelisib – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
E-3.56 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
FB-825 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
fevipiprant – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
hdm-ASIT – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Lactococcus lactis G121 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ligelizumab – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MAM-06301 – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MK-8237 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
omalizumab biosimilar – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
omalizumab biosimilar – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PIN-201601 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PRT-2607 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
quilizumab – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
RPL-554 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
S-524101 – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SB-010 – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SG-100 – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule for Allergic Asthma – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecule for Allergic Asthma – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Allergic Asthma – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules to Inhibit C-Rel for Central Nervous System, Immunology, Musculoskeletal, Oncology, Respiratory and Metabolic Disorders – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit CaMKII for Allergic Asthma – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders – Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
timothy grass pollen allergen extract – Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Vaccine for Allergic Rhinitis and Allergic Asthama – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
WF-10 – Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
WF-10 liposomal – Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Allergic Asthma – Recent Pipeline Updates 109
Allergic Asthma – Dormant Projects 131
Allergic Asthma – Discontinued Products 134
Allergic Asthma – Product Development Milestones 135
Featured News & Press Releases 135
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 135
May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 136
May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 137
Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 137
Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 138
Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 139
Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 139
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

[List of Tables]
Number of Products under Development for Allergic Asthma, H1 2015 11
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2015 23
Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 24
Allergic Asthma - Pipeline by Array BioPharma Inc., H1 2015 25
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 26
Allergic Asthma - Pipeline by Asmacure Ltee, H1 2015 27
Allergic Asthma - Pipeline by BioTech Tools s.a., H1 2015 28
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2015 29
Allergic Asthma - Pipeline by Genentech, Inc., H1 2015 30
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 31
Allergic Asthma - Pipeline by Kineta, Inc., H1 2015 32
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2015 33
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2015 34
Allergic Asthma - Pipeline by Novartis AG, H1 2015 35
Allergic Asthma - Pipeline by Nuvo Research Inc., H1 2015 36
Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2015 37
Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2015 38
Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2015 39
Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 40
Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2015 41
Allergic Asthma - Pipeline by Pulmatrix, Inc., H1 2015 42
Allergic Asthma - Pipeline by Stallergenes S.A., H1 2015 43
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 44
Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2015 45
Assessment by Monotherapy Products, H1 2015 46
Assessment by Combination Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2015 109
Allergic Asthma - Dormant Projects, H1 2015 131
Allergic Asthma - Dormant Projects (Contd..1), H1 2015 132
Allergic Asthma - Dormant Projects (Contd..2), H1 2015 133
Allergic Asthma - Discontinued Products, H1 2015 134

[List of Figures]
Number of Products under Development for Allergic Asthma, H1 2015 11
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 46
Number of Products by Top 10 Targets, H1 2015 48
Number of Products by Stage and Top 10 Targets, H1 2015 48
Number of Products by Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Top 10 Routes of Administration, H1 2015 52
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52
Number of Products by Top 10 Molecule Types, H1 2015 54
Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

【掲載企業】

ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
Asmacure Ltee
BioTech Tools s.a.
Fountain Biopharma Inc.
Genentech, Inc.
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Marinomed Biotechnologie GmbH
NeoPharm Co., Ltd.
Novartis AG
Nuvo Research Inc.
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Portola Pharmaceuticals, Inc.
Protectimmun GmbH
Pulmatrix, Inc.
Stallergenes S.A.
sterna biologicals Gmbh & Co KG
Verona Pharma Plc

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アレルギー性喘息(Allergic Asthma):治療薬開発パイプライン動向(世界、2015年上半期版)(Allergic Asthma - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆